U.S. markets close in 1 hour 55 minutes
  • S&P 500

    4,416.56
    +4.77 (+0.11%)
     
  • Dow 30

    35,111.25
    +49.70 (+0.14%)
     
  • Nasdaq

    14,827.27
    -9.72 (-0.07%)
     
  • Russell 2000

    2,210.72
    +1.07 (+0.05%)
     
  • Crude Oil

    71.92
    -0.15 (-0.21%)
     
  • Gold

    1,798.50
    -3.30 (-0.18%)
     
  • Silver

    25.30
    +0.07 (+0.27%)
     
  • EUR/USD

    1.1813
    +0.0043 (+0.37%)
     
  • 10-Yr Bond

    1.2730
    -0.0130 (-1.01%)
     
  • GBP/USD

    1.3820
    +0.0066 (+0.48%)
     
  • USD/JPY

    110.3350
    -0.1750 (-0.16%)
     
  • BTC-USD

    39,266.13
    +4,840.69 (+14.06%)
     
  • CMC Crypto 200

    934.95
    +19.46 (+2.13%)
     
  • FTSE 100

    7,025.43
    -2.15 (-0.03%)
     
  • Nikkei 225

    27,833.29
    +285.29 (+1.04%)
     

Calculating The Fair Value Of Vir Biotechnology, Inc. (NASDAQ:VIR)

  • Oops!
    Something went wrong.
    Please try again later.
·5 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Today we will run through one way of estimating the intrinsic value of Vir Biotechnology, Inc. (NASDAQ:VIR) by taking the expected future cash flows and discounting them to their present value. One way to achieve this is by employing the Discounted Cash Flow (DCF) model. Models like these may appear beyond the comprehension of a lay person, but they're fairly easy to follow.

Companies can be valued in a lot of ways, so we would point out that a DCF is not perfect for every situation. If you want to learn more about discounted cash flow, the rationale behind this calculation can be read in detail in the Simply Wall St analysis model.

See our latest analysis for Vir Biotechnology

Step by step through the calculation

We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second 'steady growth' period. To begin with, we have to get estimates of the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.

Generally we assume that a dollar today is more valuable than a dollar in the future, so we discount the value of these future cash flows to their estimated value in today's dollars:

10-year free cash flow (FCF) estimate

2022

2023

2024

2025

2026

2027

2028

2029

2030

2031

Levered FCF ($, Millions)

-US$28.1m

US$70.0m

US$113.3m

US$162.9m

US$213.9m

US$262.1m

US$304.9m

US$341.7m

US$372.5m

US$398.3m

Growth Rate Estimate Source

Analyst x2

Analyst x1

Est @ 61.8%

Est @ 43.86%

Est @ 31.3%

Est @ 22.51%

Est @ 16.35%

Est @ 12.04%

Est @ 9.03%

Est @ 6.92%

Present Value ($, Millions) Discounted @ 6.6%

-US$26.4

US$61.6

US$93.5

US$126

US$155

US$178

US$195

US$205

US$209

US$210

("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = US$1.4b

After calculating the present value of future cash flows in the initial 10-year period, we need to calculate the Terminal Value, which accounts for all future cash flows beyond the first stage. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 2.0%. We discount the terminal cash flows to today's value at a cost of equity of 6.6%.

Terminal Value (TV)= FCF2031 × (1 + g) ÷ (r – g) = US$398m× (1 + 2.0%) ÷ (6.6%– 2.0%) = US$8.8b

Present Value of Terminal Value (PVTV)= TV / (1 + r)10= US$8.8b÷ ( 1 + 6.6%)10= US$4.6b

The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is US$6.0b. To get the intrinsic value per share, we divide this by the total number of shares outstanding. Relative to the current share price of US$38.1, the company appears about fair value at a 18% discount to where the stock price trades currently. Remember though, that this is just an approximate valuation, and like any complex formula - garbage in, garbage out.

dcf
dcf

The assumptions

We would point out that the most important inputs to a discounted cash flow are the discount rate and of course the actual cash flows. Part of investing is coming up with your own evaluation of a company's future performance, so try the calculation yourself and check your own assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Vir Biotechnology as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 6.6%, which is based on a levered beta of 0.979. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

Next Steps:

Valuation is only one side of the coin in terms of building your investment thesis, and it shouldn't be the only metric you look at when researching a company. It's not possible to obtain a foolproof valuation with a DCF model. Instead the best use for a DCF model is to test certain assumptions and theories to see if they would lead to the company being undervalued or overvalued. If a company grows at a different rate, or if its cost of equity or risk free rate changes sharply, the output can look very different. For Vir Biotechnology, there are three further items you should consider:

  1. Risks: Case in point, we've spotted 4 warning signs for Vir Biotechnology you should be aware of, and 1 of them is concerning.

  2. Future Earnings: How does VIR's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.

  3. Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!

PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the NASDAQGS every day. If you want to find the calculation for other stocks just search here.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.